High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models

High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models

IntroductionImmune checkpoint inhibitors(ICIs) targeting programmed cell death protein 1 (PD1) confer significant survival benefits to patients with non-small cell lung cancer (NSCLC). However, there remains a substantial unmet need to identify therapeutic approaches to overcome resistance and provi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hak Su Kim, Seung-hyun Kwon, Ok Kyung Choi, Taekyu Lim
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	anti-PD1 high-dose ascorbic acid non-small cell lung cancer immune checkpoint inhibitors proteomic analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512605/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer
by: Sung Uk Bae, et al.
Published: (2025-03-01)

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
by: Seok Jun Park, et al.
Published: (2025-01-01)

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
by: Jie Fu, et al.
Published: (2025-01-01)

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer
by: Hiroyoshi Nozaki, et al.
Published: (2025-01-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model
by: Caroline Schoenherr, et al.
Published: (2025-01-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer
by: Yuichi Ozawa, et al.
Published: (2024-11-01)

Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer
by: Saisai Tian, et al.
Published: (2025-01-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Ascorbate-glutathione cycle in wheat and rice seedlings under anoxia and subsequent reaeration
by: V. V. Yemelyanov, et al.
Published: (2024-03-01)

High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT)
by: Yuxuan Ding, et al.
Published: (2025-02-01)

Green Synthesis of Antibacterial CuO Nanoparticles Based on the Synergy Between <i>Cornu aspersum</i> Snail Mucus and Ascorbic Acid
by: Maria Todorova, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
by: Coco Duizer, et al.
Published: (2025-12-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
by: Johannes M. Waldschmidt, et al.
Published: (2025-01-01)

Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-01-01)

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Electrochemical Sensors Based on Single-Wall Carbon Nanotubes in Voltammetric Ascorbic Acid Tests
by: Natalia V. Ivanova, et al.
Published: (2023-12-01)

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
by: Stefania Angelicola, et al.
Published: (2025-01-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

Degradation Kinetics of Ascorbic Acid in Xanthan Gum Solution
by: Runqi JIA, et al.
Published: (2025-02-01)

Dissolution of struvite stones with ascorbic acid
by: Satoshi Yoshikawa
Published: (2025-01-01)

Use of ascorbic acid (vitamin C) and alpha tocopherol (vitamin E) as adjuvants in the treatment of neuropathic pain
by: Fernando Antonio Silva de Azevedo-Filho, et al.
Published: (2025-01-01)

Colorimetric Method Based on CeO2/CoOOH Nanozyme for Rapid Detection of Ascorbic Acid in Fruits
by: YUE Xiaoyue, WU Chaoyun, YAN Shuliang, FU Long, ZHAO Dianbo
Published: (2024-12-01)